Fundraising Fox

Reprogrambio

San Carlos, US · Founded 2025 · 2 known investors

reprogrambio.com ↗

Reprogram Biosciences develops an in vivo immunotherapy that uses a therapeutic gene cocktail delivered via lipid nanoparticles to reprogram solid-tumor cancer cells into immune-like cells. The company operates in the biotech and cancer therapeutics field, applying gene reprogramming and AI-driven bioinformatics to develop cell therapies for solid tumors.

AI & Machine LearningBiotechDeep Tech

Founders & leadership

Reprogrambio was founded in 2025 by Rustam Esanov and Eziz Kuliyev.

RERustam Esanov
Rustam EsanovCo-founder & CEO
EKEziz Kuliyev
Eziz KuliyevCo-founder & COO
AYAngela Yang
Angela YangHead of Research
ATAnnageldi Tayyrov
Annageldi TayyrovHead of AI Platform

Investors · 2

Narya CapitalColumbus
Unshackled VenturesreportedPalo Alto · $300K – $500K

Reported raises · per SEC filings

Form D private placements

$6M disclosed across 2 rounds · 2025–2026

▶$5MraisedMay 2026 · 2 investors · Biotechnology
Rule 506(b)
Reprogram Biosciences Closes $6M Seed Roundallsci.com · May 2026Reprogram Biosciences Secures $6.0M | Signalbasetrysignalbase.com · May 2026
Officers, directors & promoters on the filing
  • Rustam EsanovExecutive Officer, Director
Offering amount
$5M
Amount sold
$5M
Proceeds to insiders
$150K
First sale
Mar 2026
Incorporated
Corporation, Delaware, 2025
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1MraisedMay 2025 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Rustam EsanovExecutive Officer
Offering amount
$1M
Amount sold
$1M
Proceeds to insiders
$50K
First sale
May 2025
Incorporated
Corporation, Delaware, 2025
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Transcode Therapeutics3 shared keywordsTransCode Therapeutics is a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers. Its lead candidate, TTX-MC138, targets microRNA-10b to treat patients with metastatic cancer and is in Phase 2a clinical trials.

Companies competing with Reprogrambio for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Reprogram Biosciences Closes $6M Seed Roundallsci.com · May 2026They Came to America With One Backpack Each. Now They're Reprogramming How We Fight Cancer.unshackledvc.substack.com · May 2026Reprogram Biosciences Closes Seed Financing to Advance Tumor Cell Reprogramming Therapeutics | Markets Insidermarkets.businessinsider.com · May 2026Reprogram Biosciences Secures $6.0M | Signalbasetrysignalbase.com · May 2026

Frequently asked questions

What does Reprogrambio do?
Reprogram Biosciences develops an in vivo immunotherapy that uses a therapeutic gene cocktail delivered via lipid nanoparticles to reprogram solid-tumor cancer cells into immune-like cells. The company operates in the biotech and cancer therapeutics field, applying gene reprogramming and AI-driven bioinformatics to develop cell therapies for solid tumors.
Who founded Reprogrambio?
Reprogrambio was founded by Rustam Esanov, Eziz Kuliyev in 2025.
Who are Reprogrambio's investors?
Reprogrambio's investors include Narya Capital, Unshackled Ventures.
How much funding has Reprogrambio raised?
Reprogrambio has disclosed $6M raised across 2 rounds.
Where is Reprogrambio headquartered?
Reprogrambio is headquartered in San Carlos, US.